A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma
Latest Information Update: 26 Aug 2013
At a glance
- Drugs Everolimus (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms PILLAR-3
- 24 Aug 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 12 Aug 2013 New trial record